19815-97-5 Usage
Uses
Used in Organic Synthesis:
2-BROMO-1-(2,3-DIHYDRO-1,4-BENZODIOXIN-5-YL)-1-ETHANONE is used as a key intermediate in organic synthesis for the creation of various organic compounds. Its unique structure allows for multiple synthetic pathways, making it a valuable component in the production of a range of chemical entities.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-BROMO-1-(2,3-DIHYDRO-1,4-BENZODIOXIN-5-YL)-1-ETHANONE is utilized as a building block for the development of pharmaceutical products. Its presence in the molecular structure of potential drugs can contribute to desired pharmacological properties, such as increased bioavailability or specific binding affinities to biological targets.
Used in Agrochemical Development:
2-BROMO-1-(2,3-DIHYDRO-1,4-BENZODIOXIN-5-YL)-1-ETHANONE also finds application in the agrochemical industry, where it serves as a precursor for the synthesis of compounds with pesticidal or herbicidal properties. Its reactivity and structural features are leveraged to create effective agents for crop protection and management.
Used in Drug Discovery and Development:
2-BROMO-1-(2,3-DIHYDRO-1,4-BENZODIOXIN-5-YL)-1-ETHANONE is recognized for its potential biological activities, making it an important molecule in drug discovery and development. Researchers use 2-BROMO-1-(2,3-DIHYDRO-1,4-BENZODIOXIN-5-YL)-1-ETHANONE in the design and synthesis of new drug candidates, aiming to identify novel therapeutic agents with improved efficacy and safety profiles.
Used in Research Laboratories:
2-BROMO-1-(2,3-DIHYDRO-1,4-BENZODIOXIN-5-YL)-1-ETHANONE is also used in research laboratories for studying its chemical properties and potential applications. It serves as a subject of investigation for understanding reaction mechanisms, exploring new synthetic methods, and evaluating its interactions with biological systems.
Check Digit Verification of cas no
The CAS Registry Mumber 19815-97-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,8,1 and 5 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 19815-97:
(7*1)+(6*9)+(5*8)+(4*1)+(3*5)+(2*9)+(1*7)=145
145 % 10 = 5
So 19815-97-5 is a valid CAS Registry Number.
InChI:InChI=1/C10H9BrO3/c11-6-8(12)7-2-1-3-9-10(7)14-5-4-13-9/h1-3H,4-6H2
19815-97-5Relevant academic research and scientific papers
Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors
Chang, Shaohua,Guo, Zhuang,Li, Xue,Sun, Tianwen,Wang, Hai,Wang, Xiaowei,Wang, Yazhou,Xu, Guofeng,Xu, Tianwei,Yu, Wenying,Yu, Zhuangzhuang,Zhang, Yan,Zhao, Liwen
, (2020/05/08)
Inhibition of transforming growth factor β (TGF-β) type 1 receptor (ALK5) provides a feasible approach for the treatment of fibrotic diseases and malignant tumors. In this study, we designed and synthesized a new series of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives, and evaluated biologically as TGF-β type 1 receptor inhibitors. The most potent compound 15r inhibited the ALK5 enzyme and NIH3T3 cell viability with IC50 values of 44 and 42.5 nM, respectively. Compound 15r also displayed better oral plasma exposure and excellent bioavailability than LY-3200882, and in vivo inhibited 65.7% of the tumor growth in a CT26 xenograft mouse model.
Development of new highly potent imidazo[1,2-b[pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1
Moine, Espérance,Dimier-Poisson, Isabelle,Enguehard-Gueiffier, Cécile,Logé, Cédric,Pénichon, Mélanie,Moiré, Nathalie,Delehouzé, Claire,Foll-Josselin, Beátrice,Ruchaud, Sandrine,Bach, Stéphane,Gueiffier, Alain,Debierre-Grockiego, Fran?oise,Denevault-Sabourin, Caroline
, p. 80 - 105 (2015/11/02)
Using a structure-based design approach, we have developed a new series of imidazo[1,2-b]pyridazines, targeting the calcium-dependent protein kinase-1 (CDPK1) from Toxoplasma gondii. Twenty derivatives were thus synthesized. Structure-activity relationships and docking studies confirmed the binding mode of these inhibitors within the ATP binding pocket of TgCDPK1. Two lead compounds (16a and 16f) were then identified, which were able to block TgCDPK1 enzymatic activity at low nanomolar concentrations, with a good selectivity profile against a panel of mammalian kinases. The potential of these inhibitors was confirmed in vitro on T. gondii growth, with EC50 values of 100 nM and 70 nM, respectively. These best candidates also displayed low toxicity to mammalian cells and were selected for further in vivo investigations on murine model of acute toxoplasmosis.
